Is BPC-157 legal in 2026?

On July 23, 2026 the FDA advisory committee (PCAC) voted to recommend BPC-157 for the 503A Bulks List, against FDA staff advice. A recommendation is not FDA approval or authorization to compound, and it is not availability. BPC-157 is not available to buy, waitlist only; legitimate access would require FDA rulemaking, realistically late 2026 into 2027.

When is the FDA peptide meeting?

The FDA's Pharmacy Compounding Advisory Committee (PCAC) reviewed peptides on July 23–24, 2026. On day one it voted to recommend BPC-157, KPV, TB-500 and MOTS-c for the 503A Bulks List; the recommendation is advisory and requires FDA rulemaking before any legitimate availability.

Can I buy TB-500 right now?

No. On July 23, 2026 PCAC voted to recommend TB-500 for the 503A Bulks List, but that recommendation is advisory, not FDA approval or availability. TB-500 remains waitlist-only and is not available to prescribe today.

The honest status of every peptide everyone’s asking about.

We track what’s legal, what’s under review, and what you can actually get, with FDA sources and dates. Two signals, never collapsed: what the regulation says, and whether you can get it.

Last updated July 26, 2026.

Molecule	Regulatory status (what the rule says)	Verdict (can you get it)	Next milestone	Source
BPC-157 Recovery peptide	PCAC recommended · rulemaking pending	Waitlist / coming	FDA rulemaking decision — Projected 2027	FDA source
TB-500 Soft-tissue recovery	PCAC recommended · rulemaking pending	Waitlist / coming	FDA rulemaking decision — Projected 2027	FDA source
KPV Gut anti-inflammatory	PCAC recommended · rulemaking pending	Waitlist / coming	FDA rulemaking decision — Projected 2027	FDA source
MOTS-c Mitochondrial metabolic peptide	PCAC recommended · rulemaking pending	Waitlist / coming	FDA rulemaking decision — Projected 2027	FDA source
DSIP (Emideltide) Sleep-regulating peptide	PCAC declined · not on Bulks List path	Waitlist / coming	No near-term FDA pathway	FDA source
Semax Nootropic focus peptide	PCAC recommended · rulemaking pending	Waitlist / coming	FDA rulemaking decision — Projected 2027	FDA source
Epitalon Longevity sleep peptide	PCAC recommended · rulemaking pending	Waitlist / coming	FDA rulemaking decision — Projected 2027	FDA source
CJC-1295 GH peptide	Category 2, not under current review	Not available	No scheduled FDA review	FDA source
Ipamorelin GH peptide	Category 2, not under current review	Not available	No scheduled FDA review	FDA source
PT-141 Libido arousal peptide	Restricted	Waitlist / coming	Bulks rulemaking (projected) — 2026–2027	FDA source
Sermorelin Hormone-support peptide	503A eligible (Category 1)	Available now	Compoundable now — Current	FDA source
Gonadorelin Hormone-support peptide	503A eligible (Category 1)	Available now	Compoundable now — Current	FDA source
NAD+ Cellular-energy coenzyme	503A eligible (Category 1)	Available now	Compoundable now — Current	FDA source
Vitamin B12 Methylcobalamin injection	503A eligible (Category 1)	Available now	Compoundable now — Current	FDA source
GHK-Cu (topical) Topical copper peptide	Legal, cosmetic / topical	Available now	Cosmetic use, unaffected — Ongoing	FDA source
GHK-Cu (injectable) Injectable copper peptide	Under PCAC review, 2nd batch	Waitlist / coming	Second PCAC review — By end of Feb 2027	FDA source
Rapamycin mTOR longevity drug	503A eligible	Available now	Compoundable now — Current	FDA source
TRT / Enclomiphene Testosterone hormone therapy	503A eligible · SKU pending	Waitlist / coming	Fulfillment confirmation (pending) — 2026	FDA source
Semaglutide GLP-1 weight-loss	503A / shortage-exception pathway	Available now	503B comments close — Jun 29, 2026	FDA source
Tirzepatide Dual GIP/GLP-1	503A / shortage-exception pathway	Available now	503B comments close — Jun 29, 2026	FDA source
Liraglutide GLP-1 weight-loss	503A / shortage-exception pathway	Available now	503B comments close — Jun 29, 2026	FDA source
Melanotan II Tanning melanocortin peptide	Expected to stay restricted	Not available	Second PCAC review — By end of Feb 2027	FDA source
GHRP-2 / GHRP-6 GH-releasing peptides	Expected to stay restricted	Not available	Status review (projected) — 2026–2027	FDA source
Dihexa Research-stage cognition peptide	Under PCAC review, 2nd batch (projected Feb 2027)	Waitlist / coming	Second PCAC review — By end of Feb 2027	FDA source
LL-37 Antimicrobial host peptide	Expected to stay restricted	Not available	Second PCAC review — By end of Feb 2027	FDA source
PEG-MGF Muscle growth factor	Expected to stay restricted	Not available	Second PCAC review — By end of Feb 2027	FDA source
Retatrutide Triple GLP-1/GIP/glucagon	Investigational (Phase 3)	Waitlist / coming	TRIUMPH Phase-3 readout (projected) — 2026–2027	FDA source
Cagrilintide Long-acting amylin analog	Investigational (Phase 3)	Waitlist / coming	CagriSema / REDEFINE readouts — 2026–2027	FDA source
Survodutide GLP-1/glucagon · MASH	Investigational (Phase 3)	Waitlist / coming	SYNCHRONIZE Phase-3 (projected) — 2026–2027	FDA source
VK2735 (Viking) Dual GLP-1/GIP · oral	Investigational (Phase 2/3)	Waitlist / coming	VANQUISH program (projected) — 2026–2027	FDA source
SS-31 / Elamipretide Mitochondrial cardiolipin binder	Approved (Barth) · off-label otherwise	Waitlist / coming	Longevity use remains off-label — Ongoing	FDA source

Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality. Where that applies, we say so, plainly.

PCAC is advisory: its Jul 2026 recommendation leads to rulemaking, not instant availability. A favorable advisory vote is a recommendation, not FDA approval or authorization to compound. Realistic earliest legitimate access is late 2026 into 2027. Reclassification is not the same as FDA approval. Compounded medications are not evaluated or approved by the FDA for safety, efficacy, or quality, where that applies, we say so, plainly.